2 research outputs found
Verification of the Biomarker Candidates for Non-small-cell Lung Cancer Using a Targeted Proteomics Approach
Lung cancer, with
its high metastatic potential and high mortality
rate, is the worldwide leading cause of cancer-related deaths. High-throughput
āomicsā-based platforms have accelerated the discovery
of biomarkers for lung cancer, and the resulting candidates are to
be evaluated for their diagnostic potential as noninvasive biomarkers.
The evaluation of the biomarker candidates involves the quantitative
measurement of large numbers of proteins in bodily fluids using advanced
mass spectrometric techniques. In this study, a robust pipeline based
on targeted proteomics was developed for biomarker verification in
plasma samples and applied to verifying lung cancer biomarker candidates.
Highly multiplexed liquid chromatrography-selected reaction monitoring
(LC-SRM) assays for 95 potential tumor markers for non-small-cell
lung cancer (NSCLC) were generated to screen plasma samples obtained
from 72, early to late stage, patients. A total of 17 proteins were
verified as potent tumor markers detectable in plasma and, where available,
verified by enzyme-linked immunosorbent assays (ELISAs). A novel plasma-based
biomarker, zyxin, fulfilled the criteria for a potential early diagnostic
marker for NSCLC
Achieving thoracic oncology data collection in Europe: a precursor study in 35 countries
Background: A minority of European countries have participated in international comparisons with high level data on lung cancer. However, the nature and extent of data collection across the continent is simply unknown, and without accurate data collection it is not possible to compare practice and set benchmarks to which lung cancer services can aspire.
Methods: Using an established network of lung cancer specialists in 37 European countries, a survey was distributed in December 2014. The results relate to current practice in each country at the time, early 2015. The results were compiled and then verified with co-authors over the following months.
Results: Thirty-five completed surveys were received which describe a range of current practice for lung cancer data collection. Thirty countries have data collection at the national level, but this is not so in Albania, Bosnia-Herzegovina, Italy, Spain and Switzerland. Data collection varied from paper records with no survival analysis, to well-established electronic databases with links to census data and survival analyses.
Conclusion: Using a network of committed clinicians, we have gathered validated comparative data reporting an observed difference in data collection mechanisms across Europe. We have identified the need to develop a well-designed dataset, whilst acknowledging what is feasible within each country, and aspiring to collect high quality data for clinical research.</p